|
|
|
|
|
|
|
|
|
|
|
|
|
FORM 10-Q
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
(Mark One)
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 1995
OR
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Commission file number 0-11232
VEREX LABORATORIES, INC.
(Exact name of Registrant as specified in its charter)
Colorado 84-0850695
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
14 Inverness Drive East, D-100 Englewood, Colorado 80112
(Address of principal executive offices)
(303) 799-4499
(Registrant's telephone number, including area code)
(Former name, former address and former fiscal year,
if changed since last report.)
Indicate by check mark whether the registrant (1) has filed all reports
required to filed by Section 13 or 15(d) of the Securities Exchange Act
of 1934 during the preceding 12 months (or for such shorter period that
the registrant was required to file such reports), and (2) has been
subject to such requirements for the past 90 days.
Yes X No
APPLICABLE ONLY TO CORPORATE ISSUERS:
Indicate the number of shares outstanding of each of the issuer's classes
of common stock, as of the latest practicable date.
The registrant had 2,041,538 shares of its no par value common stock
outstanding as of September 30, 1995.
<PAGE>
PART I FINANCIAL INFORMATION
- -
Item 1. Consolidated Financial Statements:
Unaudited consolidated balance sheet
Unaudited consolidated statement of
operations for the nine-month periods
Unaudited consolidated statement of
cash flows for the nine-month periods
Notes to unaudited consolidated 5
financial statements
Item 2. Management's Discussion and Analysis
of Financial Condition and Results of 6
Operations
PART II OTHER INFORMATION 7
PART III FINANTIAL DATA SCHEDULE 8
<PAGE>
SIGNATURE PAGE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant had duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
VEREX LABORATORIES, INC.
James M. Dunn, M.D.
President, Chief Executive Officer
and Chief Financial Officer
Date November 16, 1995
<TABLE> <S> <C>
<ARTICLE> 5
<LEGEND>
This schedulle contains summary financial information extracted from the
consolidated Balance sheets and consolidated statements of operations
found on pages 3 and 4 of the company's form 10-q for the year-to-date,
and is qualified in its entirety by reference to such financial statements.
</LEGEND>
<MULTIPLIER> 1,000
<S> <C>
<PERIOD-TYPE> 9-MOS
<FISCAL-YEAR-END> DEC-31-1995
<PERIOD-END> SEP-30-1995
<CASH> 34
<SECURITIES> 0
<RECEIVABLES> 17
<ALLOWANCES> 2
<INVENTORY> 13
<CURRENT-ASSETS> 385
<PP&E> 494
<DEPRECIATION> 436
<TOTAL-ASSETS> 617
<CURRENT-LIABILITIES> 2,487
<BONDS> 0
<COMMON> 2,041
0
0
<OTHER-SE> 3,290
<TOTAL-LIABILITY-AND-EQUITY> 617
<SALES> 74
<TOTAL-REVENUES> 75
<CGS> 49
<TOTAL-COSTS> 389
<OTHER-EXPENSES> 0
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 31
<INCOME-PRETAX> 0
<INCOME-TAX> 0
<INCOME-CONTINUING> 0
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> (314)
<EPS-PRIMARY> (.15)
<EPS-DILUTED> (.15)
|
|